Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 RSV Vaccine in Adults ≥60 Years of Age
NCT05127434Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2021
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Any Solicited Adverse Reactions at 7 days, Number of Participants With Unsolicited Adverse Events at 28 days and 4 more. Started Nov 2021; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05127434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127434.